These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30844857)

  • 1. Targeting proprotein convertase subtilisin/kexin type 9 in mice and monkeys.
    Wang Y; Ma M; Wang JA; Daugherty A; Lu HS
    Curr Opin Lipidol; 2019 Apr; 30(2):154-155. PubMed ID: 30844857
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
    Lu H; Howatt DA; Balakrishnan A; Graham MJ; Mullick AE; Daugherty A
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1753-7. PubMed ID: 27470509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of atherosclerosis in mice and hamsters without germline genetic engineering.
    Bjørklund MM; Hollensen AK; Hagensen MK; Dagnaes-Hansen F; Christoffersen C; Mikkelsen JG; Bentzon JF
    Circ Res; 2014 May; 114(11):1684-9. PubMed ID: 24677271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia.
    Cansby E; Magnusson E; Nuñez-Durán E; Amrutkar M; Pedrelli M; Parini P; Hoffmann J; Ståhlman M; Howell BW; Marschall HU; Borén J; Mahlapuu M
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1723-1737. PubMed ID: 29930001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.
    Roche-Molina M; Sanz-Rosa D; Cruz FM; García-Prieto J; López S; Abia R; Muriana FJ; Fuster V; Ibáñez B; Bernal JA
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):50-9. PubMed ID: 25341796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of Monoclonal PCSK9-Antibodies - New Approaches to the Therapy of Hypercholesterolemia.
    Neumann CL; Schettler E; Schettler VJ
    Blood Purif; 2016; 41(4):270-6. PubMed ID: 26789774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atherosclerosis Induced by Adeno-Associated Virus Encoding Gain-of-Function PCSK9.
    Bjørklund MM; Bernal JA; Bentzon JF
    Methods Mol Biol; 2022; 2419():461-473. PubMed ID: 35237981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The LEPIS-HuR-TMOD4 axis regulates hepatic cholesterol homeostasis and accelerates atherosclerosis.
    LYu P; Pan H; Hu K; Xue Y; Li Q; Lin R; Zheng S; Guo Z; Guo K
    Atherosclerosis; 2024 Jun; 393():117554. PubMed ID: 38663275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.
    Jarrett KE; Lee C; De Giorgi M; Hurley A; Gillard BK; Doerfler AM; Li A; Pownall HJ; Bao G; Lagor WR
    Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):1997-2006. PubMed ID: 30026278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
    Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
    Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol.
    Seidah NG
    Nat Struct Mol Biol; 2017 Oct; 24(10):785-786. PubMed ID: 28981076
    [No Abstract]   [Full Text] [Related]  

  • 13. Absence of Nicotinamide Nucleotide Transhydrogenase in C57BL/6J Mice Exacerbates Experimental Atherosclerosis.
    Vozenilek AE; Vetkoetter M; Green JM; Shen X; Traylor JG; Klein RL; Orr AW; Woolard MD; Krzywanski DM
    J Vasc Res; 2018; 55(2):98-110. PubMed ID: 29455203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol.
    Wang L; Smith J; Breton C; Clark P; Zhang J; Ying L; Che Y; Lape J; Bell P; Calcedo R; Buza EL; Saveliev A; Bartsevich VV; He Z; White J; Li M; Jantz D; Wilson JM
    Nat Biotechnol; 2018 Sep; 36(8):717-725. PubMed ID: 29985478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.
    Ascaso JF
    Endocrinol Nutr; 2016; 63(6):255-7. PubMed ID: 27050861
    [No Abstract]   [Full Text] [Related]  

  • 17. Vaccine Against PCSK9 Improved Renal Fibrosis by Regulating Fatty Acid β-Oxidation.
    Wu D; Zhou Y; Pan Y; Li C; Wang Y; Chen F; Chen X; Yang S; Zhou Z; Liao Y; Qiu Z
    J Am Heart Assoc; 2020 Jan; 9(1):e014358. PubMed ID: 31870234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Inhibition or Deletion of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) on Intracerebral Hemorrhage Volumes in Mice.
    Schlunk F; Fischer P; Princen HMG; Rex A; Prinz V; Foddis M; Lütjohann D; Laufs U; Endres M
    Stroke; 2020 Nov; 51(11):e297-e298. PubMed ID: 33070710
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential role of lycopene in targeting proprotein convertase subtilisin/kexin type-9 to combat hypercholesterolemia.
    Sultan Alvi S; Ansari IA; Khan I; Iqbal J; Khan MS
    Free Radic Biol Med; 2017 Jul; 108():394-403. PubMed ID: 28412198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.